Samsung Biologics Revenue vs. Current Valuation

207940 Stock   929,000  29,000  3.03%   
Based on Samsung Biologics' profitability indicators, Samsung Biologics Co may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Samsung Biologics' ability to earn profits and add value for shareholders.
For Samsung Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Samsung Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Samsung Biologics Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Samsung Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Samsung Biologics Co over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Samsung Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Samsung Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Samsung Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Samsung Biologics Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Samsung Biologics's current stock value. Our valuation model uses many indicators to compare Samsung Biologics value to that of its competitors to determine the firm's financial worth.
Samsung Biologics Co is the top company in revenue category among its peers. It also is the top company in current valuation category among its peers reporting about  37.57  of Current Valuation per Revenue. Comparative valuation analysis is a catch-all model that can be used if you cannot value Samsung Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Samsung Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Samsung Revenue vs. Competition

Samsung Biologics Co is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 10.25 Trillion. Samsung Biologics retains roughly 1.57 Trillion in revenue claiming about 15% of stocks in Biotechnology industry.

Samsung Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Samsung Biologics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
1.57 T
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Samsung Biologics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
58.92 T
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Samsung Current Valuation vs Competition

Samsung Biologics Co is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 71.27 Trillion. Samsung Biologics totals roughly 58.92 Trillion in current valuation claiming about 83% of stocks in Biotechnology industry.

Samsung Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Samsung Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Samsung Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Samsung Biologics' important profitability drivers and their relationship over time.

Use Samsung Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Samsung Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Samsung Biologics will appreciate offsetting losses from the drop in the long position's value.

Samsung Biologics Pair Trading

Samsung Biologics Co Pair Trading Analysis

The ability to find closely correlated positions to Samsung Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Samsung Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Samsung Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Samsung Biologics Co to buy it.
The correlation of Samsung Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Samsung Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Samsung Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Samsung Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Samsung Biologics position

In addition to having Samsung Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Preferred Stock ETFs Thematic Idea Now

Preferred Stock ETFs
Preferred Stock ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Preferred Stock ETFs theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Preferred Stock ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Samsung Stock

To fully project Samsung Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Samsung Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Samsung Biologics' income statement, its balance sheet, and the statement of cash flows.
Potential Samsung Biologics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Samsung Biologics investors may work on each financial statement separately, they are all related. The changes in Samsung Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Samsung Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.